This study concerns me because I too chose to have adjuvant HT in my protocol. My oncologist has not been impressed with recent studies on LHRH agonists (Lupron, Zoladex, Trelstar, Eligard...etc.) that are showing increased hearts risks with these drugs. However this study does show a 100% increase in all cause mortality in patients that used neo-adjuvant or adjuvant HT prior to or during brachytherapy. prostatecancerinfolink.net/2011/07/19/impact-of-adt-on-all-cause-mortality-in-men-treated-with-brachytherapy-based-radiation-therapy/
I know we have seen a survival benefit with these drugs used in such manners but the benefits appear to be mixed. If is confirmed that LHRH drugs are decreasing death by prostate cancer while increase death by other causes then it should be considered when addressing which protocol they are choosing to treat their prostate cancer. I don't think it matters what primary therapy is used but I do know that many times brachytherapy patients will be put on this regimen prior to starting seed placement to improve its effectiveness and that these patients should probably make their doctors aware if they have any heart ailment.
Advanced Prostate Cancer at age 44 (I am 49 now)
pT3b,N0,Mx (original PSA was 19.8) EPE, PM, SVI. Gleason 4+3=7
Da Vinci Surgery ~ 2/16/2007
Adjuvant Radiation Therapy ~ IMRT Completed 8/07
Adjuvant Hormone Therapy ~ 28 months on Casodex and Lupron.